Status:
NOT_YET_RECRUITING
Quantitative Measurement of Plasma and Urine MTB Cell-free DNA Level
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Tuberculosis
Eligibility:
All Genders
18+ years
Brief Summary
Tuberculosis (TB) is one of the leading causes of infectious disease worldwide. The diagnosis of TB typically relies on microbiological evidence of the presence of Mycobacterium tuberculosis (MTB) or ...
Eligibility Criteria
Inclusion
- TB group: patients hospitalized for newly diagnosed TB disease.
- LTBI group: patients without TB disease, but with LTBI diagnosed by either tuberculin skin test (TST) or an interferon-gamma release assay (IGRA) blood test.
- Control group: patients or healthy volunteers without TB disease and LTBI
Exclusion
- History of prior TB disease.
- Concomitant use of at least two first-line anti-TB drugs for at least 2 weeks in the past 3 months.
- Aged 17 years or younger
- Life expectancy of less than 12 months
- Failed to obtain informed consent due to the patient's refusal or cognitive impairment
Key Trial Info
Start Date :
January 1 2026
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2027
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT07170735
Start Date
January 1 2026
End Date
June 30 2027
Last Update
December 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince of Wales Hospital
Hong Kong, Hong Kong, Hong Kong